Valuation : Myriad Genetics, Inc.

Market Cap 309M 266M 249M 228M 426M 29.21B 429M 2.95B 1.15B 14.92B 1.16B 1.13B 48.07B P/E 2026 *
-2.03x
P/E 2027 * -2.58x
Enterprise Value 309M 266M 249M 228M 426M 29.21B 429M 2.95B 1.15B 14.92B 1.16B 1.13B 48.07B EV / Sales 2026 *
0.4x
EV / Sales 2027 * 0.38x
Free-Float
96.03%
Yield 2026 *
-
Yield 2027 * -
1 day-0.15%
1 week+1.73%
Current month+0.47%
1 month+7.12%
3 months-26.48%
6 months-38.85%
Current year-47.40%
1 week 2.92
Extreme 2.92
3.35
1 month 2.84
Extreme 2.835
3.35
Current year 2.74
Extreme 2.74
7.15
1 year 2.74
Extreme 2.74
8.59
3 years 2.74
Extreme 2.74
29.3
5 years 2.74
Extreme 2.74
36.39
10 years 2.74
Extreme 2.74
50.44
Manager TitleAgeSince
Chief Executive Officer 54 30/04/2025
Director of Finance/CFO 43 16/08/2025
Chief Tech/Sci/R&D Officer - 01/06/2026
Director TitleAgeSince
Chairman 67 23/03/2020
Director/Board Member 71 10/06/2010
Director/Board Member 66 25/09/2019
Date Insider Type Main position Quantity % Market Cap. Importance
16/8/26 Tax

Chief Financial Officer

-8,761 0.0093%
11/6/26 Free

Chief Executive Officer

3,542 0.0038%
4/6/26 Free

Director

59,701 0.0632%
Change 5-day change 1-year change 3-year change Capi.($)
-0.15%+1.73%-52.43%-81.21% 309M
-1.36%-4.69%+146.88%+354.89% 21.88B
+0.46%+2.22%-34.41%-19.73% 10.31B
+2.93%-2.64%+373.28%+20.30% 8.03B
+1.01%-5.12%-31.98% - 7.01B
+0.11%+0.34%+82.80%+52.63% 6.58B
-0.65%-2.39%-19.20%-20.52% 5.92B
+0.50%-0.31%-9.97%-20.34% 4.38B
-0.26%+1.36%+73.96%+83.74% 4.26B
-0.42%-1.38%-19.61%-27.96% 2.8B
Average +0.20%-1.50%+50.93%+37.98% 7.15B
Weighted average by Cap. +0.01%-2.62%+87.63%+125.84%

Financials

2026 *2027 *
Net sales 778M 669M 628M 574M 1.07B 73.51B 1.08B 7.43B 2.89B 37.57B 2.92B 2.86B 121B 821M 706M 663M 606M 1.13B 77.58B 1.14B 7.84B 3.05B 39.65B 3.08B 3.01B 128B
Net income -143M -123M -116M -106M -198M -13.55B -199M -1.37B -533M -6.92B -538M -526M -22.3B -106M -91.3M -85.68M -78.39M -146M -10.03B -147M -1.01B -395M -5.13B -398M -390M -16.51B
Net Debt - -
Logo Myriad Genetics, Inc.
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
Employees
2,700
Date Price Change Volume
04/09/26 US$3.225 -0.15% 523,667
02/09/26 US$3.230 +1.57% 1,351,143
01/09/26 US$3.180 -1.24% 3,034,116
31/08/26 US$3.220 +1.90% 1,543,036
28/08/26 US$3.160 -0.63% 1,429,695
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
9
Last Close Price
3.230USD
Average target price
3.338USD
Spread / Average Target
+3.33%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MYGN Stock